germ cell tumors epidemiology forecast

Key Highlights

• Germ Cell Tumors (GCTs) are a unique and diverse group of neoplasms that arise from primordial germ cells, which are the precursors to gametes.
• The incidence of GCT is around 10,900 cases in the US in 2020, which is expected to increase around 11,500 cases in US in 2034. 
• In the United States, around 9600 males and 1300 females had GCT Cases in 2020, which will increase to around 10,100 males and 1,380 females by 2034.
• Among EU4 countries and the UK, Germany accounted for the highest cases in 2020. As per estimates, in 2020, the total incident population of GCTs in EU4 and the UK had 10,840 males and 1,760 females, which will increase to 11,240 males and 1,830 females by 2034.
• In Japan, In 2020, the type-specific incidence cases of GCTs in Japan was approximately 2,100 cases for gonadial type and 90 cases for extragonadial type, which is estimated to increase up to 2,180  cases, and 91 cases, respectively by 2034.

DelveInsight’s “Germ Cell Tumors– Epidemiology – 2034” report delivers an in-depth understanding of Germ Cell Tumors, historical and forecasted epidemiology of Germ Cell Tumors in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.

Geography Covered

• The United States
• EU4 (Germany, France, Italy, and Spain) and the United Kingdom
• Japan

Study Period: 2021-2034

Germ Cell TumorsDisease Understanding 

Germ Cell Tumors Overview

GCTs are a unique and diverse group of neoplasms that arise from primordial germ cells, which are the precursors to gametes. While they are predominantly found in the gonads—the testes in males and ovaries in females—these tumors can also occur in extragonadal sites such as the mediastinum, retroperitoneum, and central nervous system, areas along the midline of the body where germ cells may aberrantly migrate during embryonic development. GCTs account for a significant proportion of neoplasms in specific age groups, such as testicular cancer in males aged 15–35 years, making them a critical focus in oncology.

Germ Cell Tumors Diagnosis

The diagnosis of germ cell tumors (GCTs) involves clinical history, physical examination, imaging (CT, MRI), and serum tumor markers such as AFP, ß-hCG, and LDH. For ovarian GCTs, markers like AFP and ß-hCG are crucial, with imaging and histological evaluation confirming the diagnosis. Testicular GCTs require immunohistochemistry for subtype identification using markers like OCT3/4, CD117, CD30, and SALL4. Extragonadal GCTs are diagnosed via cytology, biopsy, immunohistochemistry, and elevated serum markers (AFP, ß-hCG, LDH). Emerging biomarkers like miR-371a-3p enhance sensitivity and specificity for GCT detection.

Further details related to diagnosis are provided in the report…

Germ Cell Tumors Epidemiology

The Germ Cell Tumors epidemiology chapter in the report provides historical as well as forecasted epidemiology segmented by the Total Incidence Cases of GCT, Type-specific Incidence Cases of GCT, Age-specific Cases of GCT, Sub-type specific Cases of Gonadal GCT, Gender-specific Incidence Cases of GCTs, Total Incident Cases of GCTs by Stage, Total treatable Patient pool of GCT, Total Treatable Cases of GCT by Line of Therapy in the 7MM market covering the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan from 2021 to 2034. 

• In the 7MM, individuals 30-44 years of age were the most affected by GCT, with approximately 11,390 cases reported in 2023. This number is projected to increase to 11,770 by 2034.
• The total incident cases of GCT in the 7MM is expected to reach approximately 26,860 by 2034 from 25,770 in 2020.
• In Japan, In 2020, the type-specific incidence cases of GCTs in Japan was approximately 2,150 cases for gonadal type and 90 cases for extragonadal type, which is estimated to increase up to approximately 2,180  cases, and 90 cases, respectively by 2034.

KOL Views

To keep up with current epidemiology trends, we take KOLs and SMEs’ opinions working in the domain through primary research to fill the data gaps and validate our secondary research. Industry Experts contacted for insights on the Germ Cell Tumors evolving epidem landscape, patient reliance on conventional therapies, patient therapy switching acceptability, and drug uptake, along with challenges related to accessibility, including Physicians, Specialists, and others.

DelveInsight’s analysts connected with 30+ KOLs to gather insights; however, interviews were conducted with 15+ KOLs in the 7MM. Centers such as the University of California Los Angeles Medical Center, Professor of Massachusetts General Hospital, MD, etc., were contacted. Their opinion helps understand and validate current and emerging therapy treatment patterns or Germ Cell Tumors epidem trends. This will support the clients in potential upcoming novel treatments by identifying the overall scenario of the epidem and the unmet needs.

Scope of the Report

• The report covers a segment of key events, an executive summary, descriptive overview of Germ Cell Tumors, explaining its causes, signs and symptoms, pathogenesis, and currently available therapies.
• Comprehensive insight into the epidemiology segments and forecasts and disease progression has been provided.
• The report provides an edge while developing business strategies, understanding trends, expert insights/KOL views, and patient journeys in the 7MM.
• A detailed review of current challenges in establishing the diagnosis.

Germ Cell TumorsReport Insights

• Patient Population
• Country-wise Epidemiology Distribution
• Type-specific cases of Germ Cell Tumors

Germ Cell TumorsReport Key Strengths

• Eleven Years Forecast
• The 7MM Coverage 
• Germ Cell Tumors Epidemiology Segmentation

Germ Cell TumorsReport Assessment

• Current Diagnostic Practices

Epidemiology Insights

• What are the disease risks, burdens, and unmet needs of Germ Cell Tumors? What will be the growth opportunities across the 7MM concerning the patient population with Germ Cell Tumors?
• What is the historical and forecasted Germ Cell Tumors patient pool in the United States, EU4 (Germany, France, Italy, and Spain) the United Kingdom, and Japan?
• Which age group of Germ Cell Tumors has a high patient share?

Reasons to Buy

• Insights on patient burden/disease, evolution in diagnosis, and factors contributing to the change in the epidemiology of the disease during the forecast years.
• To understand the age-specific Germ Cell Tumors prevalence cases in varying geographies over the coming years.
• To understand the perspective of key opinion leaders around the current challenges with establishing the diagnosis and insights on the treatment-eligible patient pool.
• Detailed insights on various factors hampering disease diagnosis and other existing diagnostic challenges.